The study demonstrated that the combination of PCA3, miR-141, and kallikrein 2 separated BPH from PCa subjects and showed interesting performance in identifying PCa in patients with PSA levels lying in the grey area (4–10 μg/L) [155]. This evidence concerns the gene PCA3 and benign prostatic hyperplasia.